Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus

Molecular Oncology

Volumn 3, Issue 5-6, 2009, Pages 464-468

  Esfandyari, Tuba ^a   Tefferi, Ayalew ^b   Szmidt, Anna ^d   Alain, Tommy ^c   Zwolak, Pawel ^d   Lasho, Terra ^b   Lee, Patrick W ^e   Farassati, Faris ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Gene therapy; Herpes; HSV; Lymphomas; NHL; Oncolytic Viruses; R3616

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; ONCOLYTIC VIRUS; RAS PROTEIN; TRANSCRIPTION FACTOR ELK 1;

ARTICLE; CELL SELECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DAUDI CELL; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RAJI CELL; SIGNAL TRANSDUCTION; VIRUS STRAIN;

HERPES; HERPESVIRIDAE; SIMPLEXVIRUS;

EID: 70350574097     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2009.07.002     Document Type: Article

References (14)

1. Alain T., Hirasawa K., Pon K.J., Nishikawa S.G., Urbanski S.J., Auer Y., Luider J., Martin A., Johnston R.N., Janowska-Wieczorek A., et al. Reovirus therapy of lymphoid malignancies. Blood 100 (2002) 4146-4153
2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
3. Farassati F., and Lee P.W. Ras signalling pathway: a gateway for HSV-1 infection. ScientificWorldJournal 3 (2003) 533-535
4. Farassati F., Pan W., Yamoutpour F., Henke S., Piedra M., Frahm S., Al-Tawil S., Mangrum W.I., Parada L.F., Rabkin S.D., et al. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am. J. Pathol. 173 (2008) 1861-1872
5. Farassati F., Yang A.D., and Lee P.W. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3 (2001) 745-750
6. Jazirehi A.R., Vega M.I., Chatterjee D., Goodglick L., and Bonavida B. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res. 64 (2004) 7117-7126
7. Kawauchi K., Ogasawara T., and Yasuyama M. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia. Int. J. Hematol. 75 (2002) 508-513
8. Kurland J.F., Voehringer D.W., and Meyn R.E. The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis. J. Biol. Chem. 278 (2003) 32465-32470
9. Maclean A.R., and Brown S.M. Herpes Simplex Virus Protocols vol. 1 (1998), Humana Press Inc., Totowa:
10. Ogasawara T., Yasuyama M., and Kawauchi K. Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders. Int. J. Hematol. 77 (2003) 364-370
11. Parato K.A., Senger D., Forsyth P.A., and Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 5 (2005) 965-976
12. Roberts M.L., and Cooper N.R. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 240 (1998) 93-99
13. White C.M., Heidenreich O., Nordheim A., and Beerman T.A. Evaluation of the effectiveness of DNA-binding drugs to inhibit transcription using the c-fos serum response element as a target. Biochemistry 39 (2000) 12262-12273
14. Wilson K.E., Li Z., Kara M., Gardner K.L., and Roberts D.D. Beta 1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides. J. Immunol. 163 (1999) 3621-3628